## FORM 4

(Print or Type Responses)

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person  Yorke Justin W		2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA]									ole) % Owner		
(Last) (First) (Middle) C/O PROCESSA PHARMACEUTICALS, INC., 7380 COCA COLA DRIVE, SUITE 106		3. Date of Earliest Transaction (Month/Day/Year) 04/13/2021							r (give title belo	w)	Other (specify l	pelow)	
(Street) HANOVER, MD 21076		4. If Amendment, Date Original Filed(Month/Day/Year)  6. In _X_						_X_ Form fil	6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acquire						ired, Dispe	ed, Disposed of, or Beneficially Owned				
(Instr. 3) Date	Exenth/Day/Year) any	2A. Deemed Execution Date, if any (Month/Day/Year)	(Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)				7. Nature of Indirect Beneficial Ownership		
			Code	V	Amount	(A) or (D)	Price				or Indirect (I) (Instr. 4)	(Instr. 4)	
Common Stock 04/1	3/2021		S		6,500	D	\$ 9.86 (1)	257,972			I	By San Gabriel Fund, LLC, JMW Fund, LLC and the Richland Fund, LLC	
Common Stock 04/1	4/2021		S		9,700	D	\$ 9.42 (2)	248,272			I	By San Gabriel Fund, LLC, JMW Fund, LLC and the Richland Fund, LLC	
Common Stock								300,706	<u> </u>		D	LLC	
Reminder: Report on a separate line for each  1. Title of Derivative Conversion or Exercise (Instr. 3)  Price of Derivative Security  Security  1. Title of Derivative Security  Price of Derivative Security	Table II - Deri (e.g., 3A. Deemed Execution Date, if	ivative Securiti, puts, calls, wa 4. f Transaction Code (Instr. 8)	es Acquire	Pers cont the f d, Di tions,	ons who ained in orm disp	o respondence this follows a figure of the second state of the sec	eneficial eurities) 7. T Amo	e not requesting ntly valid		pond unle	of 10. Owners Form of	Beneficial Ownership (Instr. 4)	
			(A) or Disposed of (D) (Instr. 3, 4, and 5)		**					Reported Transaction (Instr. 4)	or Indir	ect	

	Code	V (A)	Exercisable	Expiration Date	Title	Amount or Number of Shares			
--	------	-------	-------------	--------------------	-------	--	--	--	--

#### **Reporting Owners**

		nips		
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Yorke Justin W C/O PROCESSA PHARMACEUTICALS, INC. 7380 COCA COLA DRIVE, SUITE 106 HANOVER, MD 21076	X			

### **Signatures**

s/ Justin W. Yorke by Michael B. Kirwan, as Attorney-in-Fact	04/15/2021
**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$9.65 to \$10.15, inclusive. The Reporting (1) Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$9.31 to \$9.50, inclusive. The Reporting (2) Person undertakes to provide Processa Pharmaceuticals. Inc. (the "Company") any security holder of the Company or the staff of the Securities & Exchange Commission
- (2) Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.